GlassScriptPhysician profile
Theodore D Barber
NPI 1083739205
$791.60
in general payments reported to CMS, 2019-2025
24 companies · $94.92 in 2025
The $94.92 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.79 · 2020: $58.33 · 2022: $121 · 2023: $84.46 · 2024: $359 · 2025: $94.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $127.52 | 2019-2024 | Speedicath |
| Dendreon Pharmaceuticals LLC | $91.46 | 2024-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $46.43 | 2024 | Adstiladrin |
| Laborie Medical Technologies Corp. | $42.30 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Antares Pharma, INC. | $38.81 | 2024-2025 | Xyosted |
| Janssen Biotech, INC. | $36.99 | 2019-2023 | Erleada |
| Olympus America INC. | $33.01 | 2024 | Itind System |
| Rochester Medical Corporation | $31.11 | 2020 | |
| Sun Pharmaceutical Industries INC. | $29.44 | 2024 | |
| Endo USA, INC. | $28.63 | 2024 | Xiaflex |
| Urogen Pharma, INC. | $24.90 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $24.76 | 2024 | |
| Janssen Scientific Affairs, LLC | $24.41 | 2024 | Erleada, Pipeline |
| Boston Scientific Corporation | $23.80 | 2019 | |
| Endo Pharmaceuticals INC. | $21.91 | 2023 | Xiaflex, Edex, Aveed |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.65 | 2024 | |
| Immunitybio, INC. | $20.19 | 2024 | |
| Axonics, INC. | $19.97 | 2024 | Bulkamid |
| Tolmar Pharmaceuticals, INC. | $19.86 | 2022 | |
| Amgen INC. | $19.85 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.48 | 2022 | |
| Palette Life Sciences, INC. | $15.94 | 2019 | |
| Cycle Pharmaceuticals INC | $15.74 | 2025 | Venxxiva |
| Dornier Medtech America, INC | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.